Role of Immunoinformatics in Accelerating Epitope-Based Vaccine Development against Dengue Virus
Ahmad Husein Alkaff1, Mutiara Saragih1, Mochammad Arfin Fardiansyah1, Usman Sumo Friend Tambunan1, *
Identifiers and Pagination:Year: 2020
First Page: 9
Last Page: 18
Publisher Id: TOBIOCJ-14-9
Article History:Received Date: 25/12/2019
Revision Received Date: 24/02/2020
Acceptance Date: 06/03/2020
Electronic publication date: 21/04/2020
Collection year: 2020
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Dengue Fever (DF) has emerged as a significant public health problem of international concern with its high prevalence in the tropic and subtropical regions. Dengue Virus (DENV), which is the cause of DF, consists of four serotypes of antigenically distinct viruses. The immense variation and limited identity similarity at the amino acid level lead to a problematic challenge in the development of an efficacious vaccine. Fortunately, the extensively available immunological data, the advance in antigenic peptide prediction, and the incorporation of molecular docking and dynamics simulation in immunoinformatics have directed the vaccine development towards the rational design of the epitope-based vaccine. Here, we point out the current state of dengue epidemiology and the recent development in vaccine development. Subsequently, we provide a systematic review of our validated method and tools for B- and T-cell epitope prediction as well as the use of molecular docking and dynamics in evaluating epitope affinity and stability in the discovery of a new tetravalent dengue vaccine through computational epitope-based vaccine design.